AGEN vs. SGMO, CRIS, ALGS, PSTX, SABS, DBVT, VXRT, MOLN, OMGA, and CRDL
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Sangamo Therapeutics (SGMO), Curis (CRIS), Aligos Therapeutics (ALGS), Poseida Therapeutics (PSTX), SAB Biotherapeutics (SABS), DBV Technologies (DBVT), Vaxart (VXRT), Molecular Partners (MOLN), Omega Therapeutics (OMGA), and Cardiol Therapeutics (CRDL). These companies are all part of the "biological products, except diagnostic" industry.
Agenus (NASDAQ:AGEN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
Agenus has higher earnings, but lower revenue than Sangamo Therapeutics. Agenus is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Agenus had 6 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 10 mentions for Agenus and 4 mentions for Sangamo Therapeutics. Agenus' average media sentiment score of 0.80 beat Sangamo Therapeutics' score of 0.41 indicating that Agenus is being referred to more favorably in the media.
Agenus presently has a consensus price target of $130.00, indicating a potential upside of 918.81%. Sangamo Therapeutics has a consensus price target of $5.67, indicating a potential upside of 984.94%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Agenus.
Agenus has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
Agenus received 25 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 70.05% of users gave Agenus an outperform vote while only 62.66% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has a net margin of -146.30% compared to Agenus' net margin of -164.69%. Agenus' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.
61.5% of Agenus shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 4.8% of Agenus shares are held by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Agenus beats Sangamo Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
